The purpose of this investigation was to study whether a combination of sulphasalazine and hydroxychloroquine was superior to treatment with a single drug. The two drugs were chosen because of their low incidence of serious side effects. In addition, we aimed to determine whether previous treatment with gold salts or penicillamine affected the outcome. Finally, the selection of patients for the study from the total population of patients with RA at the three participating rheumatological clinics was recorded.
Patients and methods

PATIENTS
During the inclusion period 776 patients with RA were registered in the three participating departments. Ninety one of these met the criteria for inclusion in the trial. They all had RA defined according to the American Rheumatism Association 1958 criteria.' The mean age was 61 years (range 18-82) and the male to female ratio was 35:56. The mean duration of RA was 6-3 years (range 0-37) and 71% belonged to Steinbrocker's functional class I and 29% to class II.2 All the patients had active disease-that is, at least three swollen joints and at least two of the following three criteria: (a) a minimum of six tender joints; (b) duration of morning stiffness of 45 minutes or longer; or (c) an erythrocyte sedimentation rate (ESR) greater than 28 mm/h. Patients were excluded based on the criteria given in table 1. The patients were randomised using a table of random numbers of three parallel groups and a double blind technique was used. The study was performed in accordance with the Helsinki declaration II and was approved by the local ethical committees. Results Thirty one patients were treated with hydroxychloroquine and placebo, 29 with sulphasalazine and placebo, and 31 with hydroxychloroquine and sulphasalazine. Sixty two patients completed the six months of treatment (23 hydroxychloroquine, 17 sulphasalazine, and 22 hydroxychloroquine and sulphasalazine). At inclusion there was no statistically significant difference between the three groups.
There was no significant difference between hydroxychloroquine and sulphasalazine treatment. Neither was there any significant difference between combination and single drug treatment with sulphasalazine. The combination treatment, but not the single drug treatment with sulphasalazine, was, however, significantly better than single drug treatment with hydroxychloroquine (ESR months 3 and 4, number of swollen joints months 4 and 6, joint pain month 3, patients' global assessments months 1-6, and doctors' global assessments months 1-5) (table 2; figs 1-3).
Radiographs of the hands and wrists showed a slight progression of the lesions specific to RA in all groups after six months of treatment (p<0 01), but there was no statistically significant difference among the three groups. The patients receiving hydroxychloroquine showed a median increase in erosions in 0-6 joints, and the patients receiving sulphasalazine or combination treatment in 0G4 joints.
Most of the patients showed no changes in lesions specific to RA during the trial and no patients showed a decrease in the number of lesions.
Of the 29 patients who withdrew from the trial (table 3), the main reasons were gastrointestinal side effects (four patients receiving sulphasalazine, six receiving hydroxychloroquine, and three receiving combination treatment) and hypersensitivity (three receiving sulphasalazine, one receiving hydroxychloroquine, and two receiving combination treatment). There was no significant difference between the three treatment groups and no serious side effects were recorded. No ophthalmological side effects to hydroxychloroquine treatment were seen.
Thirty nine patients had previously been treated with gold salts and 36 patients with penicillamine. The disease was of longer duration in these patients (mean of 12 years compared with one year), but no statistically significant difference in response to any of the drug regimens was noted in these patients.
Seven hundred and seventy six patients with RA were initially registered but 685 were excluded (table 1). The main reasons were lack of disease activity (408 patients), either due to inactive disease or ongoing treatment with disease modifying drugs (328 patients) or glucocorticosteroids (158 patients). Each patient could be registered with more than one exclusion criterion. Figure 3 Effect of drug treatment on median number of swollen joints.
Month of treatment
Discussion
In a randomised double blind study of combination treatment with sodium aurothiomalate and penicillamine McKenna et a15
found that significant clinical and biochemical improvements were seen within four weeks of combination treatment, whereas treatment with a single drug showed an effect after eight weeks; otherwise the efficacy appeared to be similar among the three groups. Scott et at found in a randomised double blind study a small advantage of combination treatment with sodium aurothiomalate and hydroxychloroquine compared with treatment with sodium aurothiomalate alone after one year of treatment. They tested 13 clinical laboratory, and radiological variables and favoured the combination treatment by 20-25%, though only the C reactive protein and an overall disease activity index differed significantly. An analysis of the transitory interaction between the two groups was not performed. Two randomised studies of a combination of antimalarial drugs and penicillamine showed no beneficial effects of the combination treatment. 7 8 Surprisingly, in one of the studies7 the group receiving combination treatment did not fare as well as the group receiving penicillamine alone. Williams et al have compared auranofin, methotrexate, and the combination of the two in a double blind randomised trial. Except for fewer withdrawals because of a lack of response, the combination treatment did not show any advantage over treatment with a single drug.
In addition to these five randomised studies a number of open studies and case reports have been published. Most of these indicated that combination treatment was effective and potentially advantageous compared with treatment with a single disease modifying antirheumatic drug.lo '4 The significant differences in this study between a combination treatment with hydroxychloroquine and sulphasalazine and treatment with a single drug (hydroxychloroquine) ( there were no indications of an increased risk by combining hydroxychloroquine and sulphasalazine (table 3) . It is possible that an increase in the dose of hydroxychloroquine could have improved the effect of this treatment as well as that of combination treatment, but we chose a relatively small dose (250 mg/day) to avoid ophthalmological side effects, which may be a risk, particularly in long term treatment. Lower doses of hydroxychloroquine were used in some studies."8 For hydroxychloroquine and sulphasalazine we chose fixed, not weight related, doses to make it possible to carry out a double blind trial.
Most studies have shown more side effects if combination treatment was used.6 8 10-12 There was no indication of an increased risk by combining hydroxychloroquine and sulphasalazine in the present study. Previous treatment with gold salts or penicillamine did not affect the response to treatment nor withdrawal profiles. At randomisation these patients had had RA for a much longer time than patients without treatment with these drugs (mean 12 years v 1 year). Previous studies have shown that the effect of disease modifying antirheumatic drugs is negatively correlated with the duration of RA, 15 possibly owing to more irreversible changes in patients with longstanding RA. In this study this was counteracted by the exclusion of patients in functional groups III and IV.
There are several possibilities for bias in controlled trials. Firstly, we had a substantial attrition of patients before randomisation because only patients referred to the participating departments could be enrolled and of these many did not fulfil the inclusion criteria ( 
